Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130 ...

"We hope our findings will help women better understand their risk of developing the disease across the course of life, so that they can make informed, individualized decisions about screening and ...

Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...

Platform can help predict a woman's 5-year risk for developing breast cancer by analyzing routine mammograms. HealthDay News — The US Food and Drug Administration has granted de novo authorization to ...

n this study, 773 untreated breast cancer patients from all over China were collected and followed up for at least 5 years. We obtained clinical data from 773 cases, RNA sequencing data from 752 cases ...

Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict five-year breast cancer risk from a routine screening mammogram. According to ...

Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium Breast and Ovarian Analysis of Disease Incidence and ...

Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among women of African ancestry. This is often due to a combination of factors, ...

Impact of postmastectomy radiotherapy on health-related quality of life and safety in breast cancer patients undergoing breast reconstruction: A multi-center cross-sectional study (Reborn-02). This is ...

The FDA granted de novo authorization to the first artificial intelligence (AI) program to support breast cancer risk prediction from screening mammograms. The program, called Clairity Breast, ...